Merrimack Pharmaceuticals Inc (MACK) Quarterly Balance Sheets

Quarterly · GAAP · USD millions
Access MACK Annual Balance Sheets →
Reviewing balance sheet data across recent quarters allows users to assess how Merrimack Pharmaceuticals Inc manages assets, liabilities, and equity through different cycles.
Quarterly Report, GAAP in USD millions
ITEM
(Mar 31 2024)
(Dec 31 2023) (Sep 30 2023) (Jun 30 2023) (Mar 31 2023)
Assets
Cash & cash equivalent234.16
Short-term Investments, Total9.95
Cash & Short-term Investments243.00
Prepaid Expense And Other Assets Current0.21
Total Current Assets244.32
Other Assets, Noncurrent0.00
Total Assets244.32
Liabilities
Accounts Payable and Accrued Liabilities, Current LI0.57
Taxes Payable, Current, Total22.11
Total Current Liabilities22.67
Total Long-term Debt0.00
Total Liabilities22.67
Stockholders' Equity
Common Stock Value1.35
Additional Paid In Capital Common Stock567.75
Retained Earnings / Accumulated Deficit-347.45
Other Equity0.00
Common Stockholder's Equity221.65
Total Stockholder's Equity221.65
Liabilities & Stockholder's Equity244.32
4 historic quarters locked

Sign in to unlock the full Merrimack Pharmaceuticals Inc balance sheet history.

About Merrimack Pharmaceuticals Inc Quarterly Balance Sheet

What this statement shows

This page presents issuer-reported balance sheet data, detailing assets, liabilities, and stockholders equity as reported in SEC 10-Q filings and standardized by CSIMarket. The balance sheet reflects the company's financial position at the end of each reporting period.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - balance-sheet normalization in the CSIMarket.com financial database.
  • Accession: 0000950170-24-060478

Balance sheet figures represent financial position at specific reporting dates and may be revised in subsequent filings.